e-learning
resources
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
Osamu Nishiyama, Kensuke Kataoka, Masahiko Ando, Shinichi Arizono, Akira Morino, Koichi Nishimura, Tomoya Ogawa, Akira Shiraki, Fumiko Watanabe, Ryo Kozu, Takashi Ogura, Yasuhiro Kondoh
Source:
ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021
Journal Issue:
July
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Osamu Nishiyama, Kensuke Kataoka, Masahiko Ando, Shinichi Arizono, Akira Morino, Koichi Nishimura, Tomoya Ogawa, Akira Shiraki, Fumiko Watanabe, Ryo Kozu, Takashi Ogura, Yasuhiro Kondoh. Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis. ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Emerging classes of drugs for the treatment of obstructive lung disease
Related content which might interest you:
Effects of short-term pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 628s
Year: 2006
The effectiveness of pulmonary rehabilitation in patients diagnosed with interstitial pulmonary fibrosis
Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care
Year: 2020
The effect of pulmonary rehabilitation on exercise tolerance pulmonary function dyspnea and quality of life in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation
Year: 2013
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Contribution of home pulmonary rehabilitation in idiopathic pulmonary fibrosis
Source: Annual Congress 2008 - Integrated care and long-term strategies
Year: 2008
Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: Comparison with COPD
Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions
Year: 2013
Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Effects of oral dual ERA therapy on pulmonary function testing and 6MWT in patients with idiopathic pulmonary fibrosis and pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Year: 2012
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
The effect of pulmonary rehabilitation programme in patients with pulmonary sarcoidosis
Source: Annual Congress 2011 - Rehabilitation, outcome measures and effects
Year: 2011
Pulmonary rehabilitation in idiopathic pulmonary fibrosis: Predictors of adherence and exercise improvement
Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation
Year: 2013
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2015; 24: 58-64
Year: 2015
A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Are the gains due to pulmonary rehabilitation in idiopathic pulmonary fibrosis and other interstitial lung diseases the same?
Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care
Year: 2020
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept